The biopharmaceutical development community
has successfully developed a broad range of highly effective therapies for a wide variety of serious and debilitating diseases. However, developing
biopharmaceuticals is inherently an extremely challenging and commercially risky undertaking, often working to tight timelines and typically resource-
constrained.
“What we have going on right now with
hESC research is the civil rights movement of the 21st century, a debate on whether science is going to enslave and manipulate the embryo,” says Samuel
Casey, managing director and general counsel for the Law of Life Project, the law firm that represented the plaintiffs in Sherley v. Sebelius. “They are the
new slaves. They are too small to vote. We are reopening the door on human subject experimentation, something that until now, only World War II closed the
door on. I have spent the last 10 years trying to point out the truth, and this is where we today.”
The University of Texas
MD Anderson Cancer Center and Trovagene Inc., a developer of transrenal molecular diagnostics, have entered into a clinical collaboration with to detect
transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers
Vanderbilt University has joined forces with AstraZeneca PLC in a
research deal to identify potential treatments for psychosis and other psychiatric symptoms associated with diseases such as Alzheimer’s and schizophrenia
Life Technologies Corp. and Boston Children’s Hospital announced in early January the launch of Claritas
Genomics, a new company formed to develop next-generation, genetic and genomics-based diagnostic testing solutions
Questcor Pharmaceuticals Inc. has signed a definitive agreement to acquire all
issued and outstanding shares of BioVectra Inc., for an upfront payment of nearly $50 million
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.